Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valneva SE
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
The partnership between Valneva and the UK government could produce the first COVID vaccine approval based on immunogenicity data.
Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis